ImmunoPrecise Antibodies Ltd. Files Form 6-K
Ticker: HYFT · Form: 6-K · Filed: Sep 3, 2025 · CIK: 1715925
Sentiment: neutral
Topics: reporting, foreign-private-issuer, press-release
TL;DR
IPA files 6-K with press release on Sept 3, 2025. Standard reporting update.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on September 3, 2025, reporting a press release dated September 3, 2025. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. Jennifer Bath signed the report on behalf of the company.
Why It Matters
This filing provides an update on ImmunoPrecise Antibodies Ltd.'s reporting status and includes a press release, which may contain material business developments.
Risk Assessment
Risk Level: low — This is a routine filing (Form 6-K) that primarily serves as an update and includes a press release, rather than announcing significant financial events or strategic shifts.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the report
- Jennifer Bath (person) — Signed the report on behalf of the company
- September 3, 2025 (date) — Date of the press release and filing
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the company has made or is required to make public pursuant to the laws of its home country, or that it has filed or will file with a stock exchange on which its securities are traded.
What specific exhibit is included with this Form 6-K?
This Form 6-K includes Exhibit 99.1, which is a Press Release dated September 3, 2025.
Which form will ImmunoPrecise Antibodies Ltd. use for its annual reports?
ImmunoPrecise Antibodies Ltd. will file its annual reports under cover of Form 20-F.
Who signed this Form 6-K filing on behalf of ImmunoPrecise Antibodies Ltd.?
Jennifer Bath signed this Form 6-K filing on behalf of ImmunoPrecise Antibodies Ltd.
What is the principal executive office address for ImmunoPrecise Antibodies Ltd. as listed in the filing?
The principal executive office address listed is Industrious, 823 Congress Ave Suite 300, Austin, Texas 78701.
Filing Stats: 144 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2025-09-03 09:21:16
Filing Documents
- press_release_september_.htm (6-K) — 25KB
- ipa-ex99_1.htm (EX-99.1) — 26KB
- 0000950170-25-112677.txt ( ) — 52KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: September 3, 2025 By: /s/ Jennifer Bath Name: Jennifer Bath Title: President and Chief Executive Officer